Cargando…

Updates on cardiovascular outcome trials in diabetes

In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnell, Oliver, Rydén, Lars, Standl, Eberhard, Ceriello, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637292/
https://www.ncbi.nlm.nih.gov/pubmed/29020969
http://dx.doi.org/10.1186/s12933-017-0610-y
_version_ 1783270597751472128
author Schnell, Oliver
Rydén, Lars
Standl, Eberhard
Ceriello, Antonio
author_facet Schnell, Oliver
Rydén, Lars
Standl, Eberhard
Ceriello, Antonio
author_sort Schnell, Oliver
collection PubMed
description In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials confirmed cardiovascular safety for all tested anti-hyperglycaemic drugs and, in addition empagliflozin, semaglutide and liraglutide could even reduce cardiovascular risk. The present review summarizes the results of the DEVOTE, CANVAS, EXSCEL and ACE trials that tested cardiovascular safety of Insulin degludec, canagliflozin, once-weekly exenatide and acarbose and were published in 2017. We provide context on these results by comparing them with earlier trials of glucose-lowering drugs and give an outlook on what to expect in coming years.
format Online
Article
Text
id pubmed-5637292
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56372922017-10-18 Updates on cardiovascular outcome trials in diabetes Schnell, Oliver Rydén, Lars Standl, Eberhard Ceriello, Antonio Cardiovasc Diabetol Review In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials confirmed cardiovascular safety for all tested anti-hyperglycaemic drugs and, in addition empagliflozin, semaglutide and liraglutide could even reduce cardiovascular risk. The present review summarizes the results of the DEVOTE, CANVAS, EXSCEL and ACE trials that tested cardiovascular safety of Insulin degludec, canagliflozin, once-weekly exenatide and acarbose and were published in 2017. We provide context on these results by comparing them with earlier trials of glucose-lowering drugs and give an outlook on what to expect in coming years. BioMed Central 2017-10-11 /pmc/articles/PMC5637292/ /pubmed/29020969 http://dx.doi.org/10.1186/s12933-017-0610-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Schnell, Oliver
Rydén, Lars
Standl, Eberhard
Ceriello, Antonio
Updates on cardiovascular outcome trials in diabetes
title Updates on cardiovascular outcome trials in diabetes
title_full Updates on cardiovascular outcome trials in diabetes
title_fullStr Updates on cardiovascular outcome trials in diabetes
title_full_unstemmed Updates on cardiovascular outcome trials in diabetes
title_short Updates on cardiovascular outcome trials in diabetes
title_sort updates on cardiovascular outcome trials in diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637292/
https://www.ncbi.nlm.nih.gov/pubmed/29020969
http://dx.doi.org/10.1186/s12933-017-0610-y
work_keys_str_mv AT schnelloliver updatesoncardiovascularoutcometrialsindiabetes
AT rydenlars updatesoncardiovascularoutcometrialsindiabetes
AT standleberhard updatesoncardiovascularoutcometrialsindiabetes
AT cerielloantonio updatesoncardiovascularoutcometrialsindiabetes
AT updatesoncardiovascularoutcometrialsindiabetes